rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Vyome Holdings, Inc.

HIND · Nasdaq

Health CareBiotechnologyNot moving yet

HIND stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 12.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
11 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders11+2 on the quarter
New · exited3 · 1
Reported value$254K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
CITADEL ADVISORS LLCnew · filed 14 Aug 202625,972$56K+25,972
GEODE CAPITAL MANAGEMENT, LLCunchanged · filed 12 Aug 202625,793$55K00.0%
Focus Partners Wealthunchanged · filed 12 Aug 202614,640$31K00.0%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202612,195$26K00.0%
UBS Group AGreduced · filed 13 Aug 202611,908$26K-10,767−47.5%
SUSQUEHANNA INTERNATIONAL GROUP, LLPnew · filed 14 Aug 202610,058$22K+10,058
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 20269,463$20K00.0%
ROYAL BANK OF CANADAunchanged · filed 14 Aug 20265,856$13K00.0%
Tower Research Capital LLC (TRC)added · filed 11 Aug 20261,808$3,887+417+30.0%
BARCLAYS PLCnew · filed 14 Aug 202626$56+26
30 Sep 2025 – 30 Jun 2026
5811Sep 25Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Mohanjit Jolly Company insiderDirector · last 1 Sep 20260 · 0
John M. Tincoff III Company insiderDirector · last 13 Nov 20250 · 0
Shiladitya Sengupta Company insiderDirector · last 13 Nov 20250 · 0
Stanley D. Pomichter III Company insiderDirector · last 13 Nov 20250 · 0
Venkateswarlu Nelabhotla Company insiderPresident and CEO · last 13 Nov 20250 · 0
Robert Dickey IV Company insiderChief Financial Officer · last 15 Aug 20250 · 0
Thomas Stankovich Company insiderChief Financial Officer · last 31 May 20245 · 33
Barton P. Bandy Company insiderPresident and CEO · last 5 Aug 20220 · 12
Dan W. Gladney Company insiderDirector · last 10 Sep 20210 · 1
Arda Phd Minocherhomjee Company insiderDirector · last 22 Jul 20210 · 0
Gary Blackford Company insiderDirector · last 22 Jul 20210 · 0
Lori Courtney McDougal Company insiderDirector · last 22 Jul 20210 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202568.4%
Research spendFY 2025 · to 31 Dec 2025184%
Share count trendFY 2025 · to 17 Mar 202618.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$5.0M

Analyst forecasts

No analyst forecasts yet.